BioCatalystWatch
BIIBWorkspace / BIIB / OverviewCompany library
Price
Market cap
Next catalystFirst half of December 2026Litifilimab — TOPAZ-1 / TOPAZ-2 and EMERALD · Phase 3 dataCompany source ↗
Cash

Chart & Events

Candle interval

Core Clinical

Lecanemab

Aβ protofibrils

PreINDP1P2P3FilingApproved

Litifilimab

BDCA2

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

Litifilimab

BDCA2

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Other pipelines

orelabrutinib

BTK

orelabrutinib

BTK

PreINDP1P2P3FilingApproved
salanersen (BIIB115)

SMN2 pre-mRNA

PreINDP1P2P3FilingApproved
orelabrutinib

BTK

orelabrutinib

BTK

FELZARTAMAB

CD38

PreINDP1P2P3FilingApproved

Partner / License out

CD20 × CD3

PreINDP1P2P3FilingApproved

CD20 × CD3

TNF

Approved

PreINDP1P2P3FilingApproved

CD20 × CD3

Approved / commercial

Lecanemab

Aβ protofibrils

Approved

PreINDP1P2P3FilingApproved
Lecanemab

Aβ protofibrils

PreINDP1P2P3FilingApproved
Upcoming / outlook

Lecanemab

Aβ protofibrils

Aβ protofibrils

PreINDP1P2P3FilingApproved

History / paused

IL-6R

PreINDP1P2P3FilingApproved

IL-6R

IL-6R

PreINDP1P2P3FilingApproved

IL-6R

PreINDP1P2P3FilingApproved

VEGF-A

Approved

PreINDP1P2P3FilingApproved

VEGF-A

Approved

PreINDP1P2P3FilingApproved

VEGF-A

Approved

PreINDP1P2P3FilingApproved

LRRK2

PreINDP1P2P3FilingApproved

LRRK2

PreINDP1P2P3FilingApproved

LINGO-1

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Operating
Investing
Financing

Reported shares and borrowings

Source and basis

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

BIIB PR & News

PR & News

BIIB SEC archive